AVALO THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
AVALO THERAPEUTICS, INC. (AVTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$36.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$36.36M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$19.63M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$30.63M, a 660.69% decline year-over-year.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$20.77M, a 576.92% decline year-over-year.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2024 was -$35.13M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$31.54M.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was $41.70M, a 436.54% increase from fiscal 2017.
- AVALO THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for fiscal 2017 was $7.77M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$36.36M 10-Q · filed 2026-08-06 | -$55.99M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$19.63M 10-Q · filed 2026-05-13 | ||||
| 2025-09-30 | -$30.63M 10-Q · filed 2025-11-06 | -$51.39M derived: sum of 2 quarters · filed 2026-08-06 | -$64.54M 10-Q · filed 2025-11-06 | -$99.70M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$20.77M 10-Q · filed 2026-08-06 | -$33.91M 10-Q · filed 2026-08-06 | -$69.08M derived: sum of 3 quarters · filed 2026-08-06 | -$63.61M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$13.15M 10-Q · filed 2026-05-13 | -$48.31M derived: sum of 2 quarters · filed 2026-05-13 | -$42.85M derived: sum of 3 quarters · filed 2026-05-13 | -$38.49M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$35.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$29.70M derived: sum of 2 quarters · filed 2026-03-23 | -$25.35M derived: sum of 3 quarters · filed 2026-03-23 | -$35.13M 10-K · filed 2026-03-23 | |
| 2024-09-30 | $5.46M 10-Q · filed 2025-11-06 | $9.82M derived: sum of 2 quarters · filed 2025-11-06 | $33.00K 10-Q · filed 2025-11-06 | -$119.64M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $4.35M 10-Q · filed 2025-08-07 | -$22.83M 10-Q · filed 2025-08-07 | -$125.10M derived: sum of 3 quarters · filed 2025-08-07 | -$130.33M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$121.29M 10-Q · filed 2025-05-12 | -$129.46M derived: sum of 2 quarters · filed 2025-05-12 | -$134.69M derived: sum of 3 quarters · filed 2025-05-12 | -$142.88M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$8.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$13.40M derived: sum of 2 quarters · filed 2025-03-20 | -$21.59M derived: sum of 3 quarters · filed 2025-03-20 | -$31.54M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$5.23M 10-Q · filed 2024-11-07 | -$13.42M derived: sum of 2 quarters · filed 2024-11-07 | -$23.38M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$8.19M 10-Q · filed 2024-08-12 | -$18.15M 10-Q · filed 2024-08-12 | |||
| 2018-12-31 | $41.70M 10-K · filed 2020-03-11 | -$41.71M 10-K · filed 2019-03-18 | |||
| 2017-12-31 | -$7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $11.53M derived: sum of 2 quarters · filed 2019-03-18 | $7.77M 10-K · filed 2019-03-18 | ||
| 2017-09-30 | $18.72M 10-Q · filed 2017-11-07 | $14.96M 10-Q · filed 2017-11-07 | |||
| 2016-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$7.81M derived: sum of 2 quarters · filed 2018-04-02 | -$16.47M 10-K · filed 2018-04-02 | ||
| 2016-09-30 | -$6.17M 10-Q · filed 2017-11-07 | -$14.83M 10-Q · filed 2017-11-07 | |||
| 2015-12-31 | -$3.65M 10-K · filed 2016-03-23 | -$4.34M derived: sum of 2 quarters · filed 2016-03-23 | -$7.25M derived: sum of 3 quarters · filed 2016-03-23 | -$10.49M 10-K · filed 2018-04-02 | |
| 2015-09-30 | -$692.00K 10-K · filed 2016-03-23 | -$3.60M derived: sum of 2 quarters · filed 2016-03-23 | -$6.84M derived: sum of 3 quarters · filed 2016-03-23 | -$9.37M derived: sum of 4 quarters · filed 2016-03-23 | |
| 2015-06-30 | -$2.91M 10-K · filed 2016-03-23 | -$6.15M derived: sum of 2 quarters · filed 2016-03-23 | -$8.67M derived: sum of 3 quarters · filed 2016-03-23 | -$1.98M derived: sum of 4 quarters · filed 2016-03-23 | |
| 2015-03-31 | -$3.24M 10-K · filed 2016-03-23 | -$5.76M derived: sum of 2 quarters · filed 2016-03-23 | $934.00K derived: sum of 3 quarters · filed 2016-03-23 | -$3.13M derived: sum of 4 quarters · filed 2016-03-23 | |
| 2014-12-31 | -$2.52M 10-K · filed 2016-03-23 | $4.17M derived: sum of 2 quarters · filed 2016-03-23 | $108.00K derived: sum of 3 quarters · filed 2016-03-23 | -$3.52M 10-K · filed 2017-03-14 | |
| 2014-09-30 | $6.70M 10-K · filed 2016-03-23 | $2.63M derived: sum of 2 quarters · filed 2016-03-23 | -$998.00K derived: sum of 3 quarters · filed 2016-03-23 | ||
| 2014-06-30 | -$4.06M 10-K · filed 2016-03-23 | -$7.69M derived: sum of 2 quarters · filed 2016-03-23 | |||
| 2014-03-31 | -$3.63M 10-K · filed 2016-03-23 | ||||
| 2013-12-31 | -$13.13M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |